Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Modelling SARS-CoV-2 Dynamics: Implications for Therapy

Kwang Su Kim, View ORCID ProfileKeisuke Ejima, Yusuke Ito, Shoya Iwanami, Hirofumi Ohashi, Yoshiki Koizumi, Yusuke Asai, Shinji Nakaoka, Koichi Watashi, Robin N. Thompson, Shingo Iwami
doi: https://doi.org/10.1101/2020.03.23.20040493
Kwang Su Kim
aDepartment of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan 8190395
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Keisuke Ejima
bDepartment of Epidemiology and Biostatistics, Indiana University School of Public Health-Bloomington, IN, USA 47405
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Keisuke Ejima
Yusuke Ito
aDepartment of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan 8190395
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shoya Iwanami
aDepartment of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan 8190395
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hirofumi Ohashi
cDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan 1628640
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshiki Koizumi
dNational Center for Global Health and Medicine, Tokyo, Japan 1628655
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yusuke Asai
dNational Center for Global Health and Medicine, Tokyo, Japan 1628655
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinji Nakaoka
eFaculty of Advanced Life Science, Hokkaido University, Sapporo, Japan 060-0808
fPRESTO, JST, Saitama, Japan 3320012
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Koichi Watashi
cDepartment of Virology II, National Institute of Infectious Diseases, Tokyo, Japan 1628640
gDepartment of Applied Biological Science, Tokyo University of Science, Noda, Japan 2788510
hMIRAI, JST, Saitama, Japan 3320012
iCREST, JST, Saitama, Japan 3320012
jInstitute for Frontier Life and Medical Sciences, Kyoto University, Kyoto, Japan 6068507
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robin N. Thompson
kChrist Church, University of Oxford, Oxford OX1 1DP, UK
lMathematical Institute, University of Oxford, Oxford OX2 6GG, UK, Fukuoka, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: robin.thompson@chch.ox.ac.uk siwami@kyushu-u.org
Shingo Iwami
aDepartment of Biology, Faculty of Sciences, Kyushu University, Fukuoka, Japan 8190395
hMIRAI, JST, Saitama, Japan 3320012
iCREST, JST, Saitama, Japan 3320012
mScience Groove Inc., Fukuoka, Japan 8100041
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: robin.thompson@chch.ox.ac.uk siwami@kyushu-u.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

The scientific community is focussed on developing antiviral therapies to mitigate the impacts of the ongoing novel coronavirus disease (COVID-19) outbreak. This will be facilitated by improved understanding of viral dynamics within infected hosts. Here, using a mathematical model in combination with published viral load data collected from the same specimen (throat / nasal swabs or nasopharyngeal / sputum / tracheal aspirate), we compare within-host dynamics for patients infected in the current outbreak with analogous dynamics for MERS-CoV and SARS-CoV infections. Our quantitative analyses revealed that SARS-CoV-2 infection dynamics are more severe than those for mild cases of MERS-CoV, but are similar to severe cases, and that the viral dynamics of SARS-CoV infection are similar to those of MERS-CoV in mild cases but not in severe case. Consequently, SARS-CoV-2 generates infection dynamics that are more severe than SARS-CoV. Furthermore, we used our viral dynamics model to predict the effectiveness of unlicensed drugs that have different methods of action. The effectiveness was measured by AUC of viral load. Our results indicated that therapies that block de novo infections or virus production are most likely to be effective if initiated before the peak viral load (which occurs around three days after symptom onset on average), but therapies that promote cytotoxicity are likely to have only limited effects. Our unique mathematical approach provides insights into the pathogenesis of SARS-CoV-2 in humans, which are useful for development of antiviral therapies.

Significance Statement Antiviral agents with different mechanisms of action have different curative effects depending on precisely when therapy is initiated. Based on a model of viral dynamics, parameterised using viral load data from SARS-CoV-2 infected patients reported by Zou et al. (1), computer simulations were performed. We propose that effective treatment of SARS-CoV-2 infection requires an appropriate choice of class-specific drugs and initiation timing as reported for treatment of other viral infections (2); otherwise, antivirals do not have a significant effect on the within-host viral dynamics of SARS-CoV-2 and are wasted.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study was supported in part by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education 2019R1A6A3A12031316 (to K.S.K.); Grants-in-Aid for JSPS Scientific Research (KAKENHI) Scientific Research B 17H04085 (to K.W.), 18KT0018 (to S.I.), 18H01139 (to S.I.), 16H04845 (to S.I.), Scientific Research S 15H05707 (to S.N.), Scientific Research in Innovative Areas 19H04839 (to S.I.), 18H05103 (to S.I.); AMED CREST 19gm1310002 (to S.I.); AMED J-PRIDE 19fm0208019j0003 (to K.W.), 19fm0208006s0103 (to S.I.), 19fm0208014h0003 (to S.I.), 19fm0208019h0103 (to S.I.); AMED Research Program on HIV/AIDS 19fk0410023s0101 (to S.I.); Research Program on Emerging and Re-emerging Infectious Diseases 19fk0108050h0003 (to S.I.); Program for Basic and Clinical Research on Hepatitis 19fk0210036j0002 (to K.W.), 19fk0210036h0502 (to S.I.); Program on the Innovative Development and the Application of New Drugs for Hepatitis B 19fk0310114j0003 (to K.W.), 19fk0310101j1003 (to K.W.), 19fk0310103j0203 (to K.W.), 19fk0310114h0103 (to S.I.); JST PRESTO (to S.N.); JST MIRAI (to K.W. and S.I.); JST CREST (to K.W. and S.I.); The Yasuda Medical Foundation (to K.W.); Smoking Research Foundation (to K.W.); Takeda Science Foundation (to K.W.); Mochida Memorial Foundation for Medical and Pharmaceutical Research (to K.W.); Mitsui Life Social Welfare Foundation (to S.I. and K.W.); Shin-Nihon of Advanced Medical Research (to S.I.); Suzuken Memorial Foundation (to S.I.); Life Science Foundation of Japan (to S.I.); SECOM Science and Technology Foundation (to S.I.); The Japan Prize Foundation (to S.I.); Toyota Physical and Chemical Research Institute (to S.I.); Fukuoka Financial Group, Inc. (to S.I.); Kyusyu Industrial Advancement Center Gapfund Program (to S.I.); Foundation for the Fusion Of Science and Technology (to S.I.); a Junior Research Fellowship from Christ Church, Oxford (to R.N.T.)

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The data used in this study were extracted from the following papers: 1. Zou L, et al. (2020) SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med. 2. Oh MD, et al. (2016) Viral Load Kinetics of MERS Coronavirus Infection. N Engl J Med 375(13):1303-1305. 3. Peiris JS, et al. (2003) Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 361(9371):1767-1772.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted March 27, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Modelling SARS-CoV-2 Dynamics: Implications for Therapy
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Modelling SARS-CoV-2 Dynamics: Implications for Therapy
Kwang Su Kim, Keisuke Ejima, Yusuke Ito, Shoya Iwanami, Hirofumi Ohashi, Yoshiki Koizumi, Yusuke Asai, Shinji Nakaoka, Koichi Watashi, Robin N. Thompson, Shingo Iwami
medRxiv 2020.03.23.20040493; doi: https://doi.org/10.1101/2020.03.23.20040493
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Modelling SARS-CoV-2 Dynamics: Implications for Therapy
Kwang Su Kim, Keisuke Ejima, Yusuke Ito, Shoya Iwanami, Hirofumi Ohashi, Yoshiki Koizumi, Yusuke Asai, Shinji Nakaoka, Koichi Watashi, Robin N. Thompson, Shingo Iwami
medRxiv 2020.03.23.20040493; doi: https://doi.org/10.1101/2020.03.23.20040493

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (168)
  • Anesthesia (51)
  • Cardiovascular Medicine (452)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (158)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (191)
  • Epidemiology (5268)
  • Forensic Medicine (3)
  • Gastroenterology (196)
  • Genetic and Genomic Medicine (759)
  • Geriatric Medicine (80)
  • Health Economics (213)
  • Health Informatics (699)
  • Health Policy (360)
  • Health Systems and Quality Improvement (224)
  • Hematology (99)
  • HIV/AIDS (164)
  • Infectious Diseases (except HIV/AIDS) (5889)
  • Intensive Care and Critical Care Medicine (363)
  • Medical Education (105)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (767)
  • Nursing (43)
  • Nutrition (131)
  • Obstetrics and Gynecology (143)
  • Occupational and Environmental Health (234)
  • Oncology (480)
  • Ophthalmology (152)
  • Orthopedics (39)
  • Otolaryngology (95)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (223)
  • Pharmacology and Therapeutics (136)
  • Primary Care Research (98)
  • Psychiatry and Clinical Psychology (864)
  • Public and Global Health (2021)
  • Radiology and Imaging (349)
  • Rehabilitation Medicine and Physical Therapy (158)
  • Respiratory Medicine (287)
  • Rheumatology (94)
  • Sexual and Reproductive Health (74)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (29)
  • Urology (39)